---
title: "NRx Pharmaceuticals, Inc. (NRXP.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NRXP.US.md"
symbol: "NRXP.US"
name: "NRx Pharmaceuticals, Inc."
industry: "Pharmaceuticals"
datetime: "2026-06-14T05:35:04.307Z"
locales:
  - [en](https://longbridge.com/en/quote/NRXP.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NRXP.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NRXP.US.md)
---

# NRx Pharmaceuticals, Inc. (NRXP.US)

## Company Overview

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.nrxpharma.com](https://www.nrxpharma.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-06-14T04:30:11.000Z

**Overall: D (0.61)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 144 / 196 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -1.78% |  |
| P/B Ratio | -9.19 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 126979699.20 |  |
| Revenue | 2293000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 125.92% | A |
| Profit Margin | -1070.21% | E |
| Gross Margin | 40.92% | B |
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -1.78% | C |
| Total Assets YoY | 56.82% | A |
| Net Assets YoY | 45.09% | A |
| Cash Flow Margin | 60.83% | C |
| OCF YoY | 0.00% | D |
| Turnover | 0.24 | D |
| Gearing Ratio | 216.07% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - NRx Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.78%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "-9.19",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "126979699.20",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2293000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "125.92%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-1070.21%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "40.92%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-1.78%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "56.82%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "45.09%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "60.83%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.24",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "216.07%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.17 | 163/196 | - | - | - |
| PB | -9.19 | 226/196 | - | - | - |
| PS (TTM) | 55.38 | 141/196 | 271.58 | 225.10 | 62.70 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-28T04:00:00.000Z

Total Analysts: **4**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.84 |
| Highest Target | 49.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NRXP.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NRXP.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NRXP.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NRXP.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**